StockTwits

This forum is to discuss general things concerning TSOI.
Codycrusher
Posts: 38
Joined: Sat Feb 13, 2021 2:29 pm

Re: StockTwits

Post by Codycrusher »

Being able to share my thoughts and reading everyone on this forum on a daily basis, considering all in all and how much I have invested, I feel this along with the massive pipeline/potential of this company, I have much faith in this company and will be here for years. Tim, this forum is 1 of the primary reasons why I get involved in this company in the first place and it keeps me having faith big time, I cannot begin to express the sort of peace of mind this brings me and us to investors us being able to share our mind and worries to you and you actually reading what we say and responding, this makes investors really happy.
User avatar
TimGDixon
Posts: 938
Joined: Fri Jun 26, 2020 4:36 am

Re: StockTwits

Post by TimGDixon »

Here's another Hall of Famer from thecuzzin. Thats me and Tom going whoa after we saw the StemVacs-V data - its WHOA!!!!! "V" is for Victory!
giphy.gif
giphy.gif (3.56 MiB) Viewed 616 times
tc.jpg
tc.jpg (311.7 KiB) Viewed 616 times
Jamesy
Posts: 10
Joined: Wed Feb 24, 2021 2:06 pm

Re: StockTwits

Post by Jamesy »

Good morning Tim!

Probably not the best place for this, but are StemVacs-V essentially the same as StemVacs2? I'm thinking that's the case, and it's just a difference in the name.
User avatar
TimGDixon
Posts: 938
Joined: Fri Jun 26, 2020 4:36 am

Re: StockTwits

Post by TimGDixon »

Yes and no. StemVacs2 is the same as StemVacs-V but the method and manner of manufacturing is different which provides for a continuous source of cells that would be consistent. The "V" is for Victory - We were going to use T for Tim&Tom but thought it was too cheesy. But we needed to differentiate it, hence the V.
Jamesy
Posts: 10
Joined: Wed Feb 24, 2021 2:06 pm

Re: StockTwits

Post by Jamesy »

I see, very interesting! So going forward, we'll be utilizing StemVacs-V in Mexico and future clinical trials rather than StemVacs2. Very cool and I can't wait to see how it all plays out. It's going to be exciting times!
User avatar
TimGDixon
Posts: 938
Joined: Fri Jun 26, 2020 4:36 am

Re: StockTwits

Post by TimGDixon »

Another Hall of Famer

User avatar
TimGDixon
Posts: 938
Joined: Fri Jun 26, 2020 4:36 am

Re: StockTwits

Post by TimGDixon »

I'm kinda liking my whole Hall of Famer's.. this is another instant classic hahahahahaha but i double award to TradersTrader and the Spicolidude who smilingly approves hahahahahahaha - you guys crack me up.
st2a.jpg
st2a.jpg (370.58 KiB) Viewed 557 times
User avatar
TimGDixon
Posts: 938
Joined: Fri Jun 26, 2020 4:36 am

Re: StockTwits

Post by TimGDixon »

Big Congratulations to the StockTwits Crew - you hit 2500 - thats incredible. I see one of our competitors CTXR has 19,000 followers - we have to beat them - we beat them in market cap recently and we probably still do and our iPSC technology pretty much neuters their iPSC product they just raised I think 100mm for. The Digger Dans can probably find that...
st3.jpg
st3.jpg (240.98 KiB) Viewed 557 times
trader32176
Posts: 2292
Joined: Fri Jun 26, 2020 5:22 am

Re: StockTwits

Post by trader32176 »

Tim,
I dug up some info on CTXR iPSC technology , and found mention of another company Cynata also :

Citius to License Novellus’ iPSC-derived MSCs for COVID-19 Related Complications


https://bioinformant.com/citius-ipsc-de ... -covid-19/

– Novellus’ patented mRNA-based cell-reprogramming technology creates MSCs with superior immunomodulatory properties
– Novellus’ iPSC-derived MSCs have manufacturing advantages over primary adult, donor-derived MSCs, allowing for larger supply, faster scale-up, and a more consistent cellular product
– MSCs may remedy the cytokine storm that triggers acute respiratory distress syndrome (ARDS) in COVID-19 patients

In a deal inked April 1, 2020, Citius Pharmaceuticals (Nasdaq: CTXR) signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, Inc. Headquartered in Cranford, New Jersey, Citius is a specialty pharmaceutical company that develops products internally, as well as in-licenses products related to compelling market opportunities.

Novellus is a pre-clinical stage biotech company in the Cambridge area of Massachusetts that creates engineered cellular medicines. It has a strong intellectual property portfolio (IP) related to RNA gene editing and RNA cell reprogramming that includes more than 30 granted patents.

The relevance of Novellus’s patented process to COVID-19 is that is uses non-immunogenic synthetic mRNA molecules to create induced pluripotent stem cells (iPSCs) that are turned into mesenchymal stem cells (MSCs). MSCs are a cell-type that have demonstrated powerful immunomodulatory properties.

MSCs have taken center stage as a intriguing tool for the treatment of patients with COVID-19 related respiratory complications. This is because there is a foundation of scientific literature and early trials to support the use of MSCs for addressing respiratory disease and distress. Currently, MSCs are being tested in more than 1,000 trials worldwide for diverse range of clinical indications, providing evidence of an acceptable safety profile.

Globally, ARDS is a leading cause of death in severe and critically ill COVID-19 patients. It is a type of respiratory failure in which rapid and severe inflammation damages the patient’s lungs, creating a mortality rate of 30% to 50%.

According to Citius’ CEO, Myron Holubiak:

“ARDS is the most common cause of respiratory failure and mortality in COVID-19 patients. Currently, there is no proven treatment for ARDS. Literature supports the use of counter-inflammatory MSCs for ARDS, and papers published in China have shown that at least seven COVID-19 patients with ARDS responded to MSC therapy. We believe Novellus is at the forefront of creating allogeneic, iPSC-derived MSCs. These cells have the potential to overcome the limitations of MSCs derived from adult donors, which are telomere shortened and introduce variability into the manufacturing process. MSCs have been studied in the treatment of lung injury, and we aim to build upon this work with Novellus’s iPSC-derived MSCs to improve the immunomodulatory response in humans. We have assembled a team of experts who are dedicated to advancing this project to an IND application as quickly as possible.”

According to Novellus’s CSO, Matt Angel, PhD:

“Using our mRNA-based cell-reprogramming technology, Novellus can provide a near-unlimited supply of MSCs for treating patients with ARDS, including those critically ill from COVID-19. These will be allogeneic (‘off-the-shelf’) cells that in vitro have demonstrated much greater expansion potential and much higher immunomodulatory protein expression than donor-derived MSCs. We are excited to employ our technology to such an urgent medical crisis and believe that our MSCs represent an ideal source of cells to be used in this extremely important development effort.”


A Competitor Exploring iPSC-Derived MSCs: Cynata Therapeutics

Another company exploring the use of iPSC-derived MSCs for the treatment of COVID-19 related complications is Cynata Therapeutics, an Australian stem cell company. Cynata’s proprietary technology utilizes iPSCs from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs), which it differentiates in MSCs.

In cases of COVID-19 that produce serious complications, such as acute respiratory distress syndrome, sepsis or cytokine release syndrome, Cynata’s Cymerus™ iPSC-derived MSCs may be positioned to serve an unmet medical need. This is because the company’s iPSC-derived MSCs have demonstrated improvements for these indications in preclinical studies.
User avatar
TimGDixon
Posts: 938
Joined: Fri Jun 26, 2020 4:36 am

Re: StockTwits

Post by TimGDixon »

I knew there were Digger Dan's out there. Thank you Trader.

Obviously this was written either before the published results of JadiCells Phase 2 Sars/CoV2/ARDS or they were naive of its existence at the time of writing. Now for sure he is correct in that there is "no proven treatment" if his use of that adjective is forward looking to a final FDA approval for ARDS. And thats exactly what we are after and we are much more advanced than they are. Let me be clear i am not tearing down their work per se - we don't do that at TSOI because we value all good research - we may compete vigorously as zealots of our own work but we won't denigrate theirs. Our work stands on its own merits sink or float.

With that said we do have a treatment that has shown great promise and we can boast here a little. In Phase 2, patients who were in ICU and mechanically ventilated due to ARDS had a 100% survival rate in the patients who received JadiCells under the age of 85 and for those over 85 it was a survival rate of 91% as compared to control who had a 42% survival rate.
According to Citius’ CEO, Myron Holubiak:

“ARDS is the most common cause of respiratory failure and mortality in COVID-19 patients. Currently, there is no proven treatment for ARDS. Literature supports the use of counter-inflammatory MSCs for ARDS, and papers published in China have shown that at least seven COVID-19 patients with ARDS responded to MSC therapy. We believe Novellus is at the forefront of creating allogeneic, iPSC-derived MSCs. These cells have the potential to overcome the limitations of MSCs derived from adult donors, which are telomere shortened and introduce variability into the manufacturing process. MSCs have been studied in the treatment of lung injury, and we aim to build upon this work with Novellus’s iPSC-derived MSCs to improve the immunomodulatory response in humans. We have assembled a team of experts who are dedicated to advancing this project to an IND application as quickly as possible.”

You see them use those magic words "off-the-shelf" - well thats exactly what Jadi's are - off the shelf *patented* universal stem cells. A single umbilical cord may contain as many as one trillion jadi cells - thats about enough to treat 5,000 patients with ARDS from medical waste. You know what you own folks - own it!
According to Novellus’s CSO, Matt Angel, PhD:

“Using our mRNA-based cell-reprogramming technology, Novellus can provide a near-unlimited supply of MSCs for treating patients with ARDS, including those critically ill from COVID-19. These will be allogeneic (‘off-the-shelf’) cells that in vitro have demonstrated much greater expansion potential and much higher immunomodulatory protein expression than donor-derived MSCs. We are excited to employ our technology to such an urgent medical crisis and believe that our MSCs represent an ideal source of cells to be used in this extremely important development effort.”
Post Reply